$1.25
6.02%
Nasdaq, Nov 20, 03:59 pm EST. Closed.
ISIN
US81750R1023
Symbol
MCRB

Seres Therapeutics Inc Stock price

$1.24
-1.07 46.32% 1M
-6.42 83.81% 6M
-13.64 91.67% YTD
-20.46 94.29% 1Y
-18.16 93.61% 3Y
-182.16 99.32% 5Y
-228.56 99.46% 10Y
-1,026.76 99.88% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
-0.09 6.77%
ISIN
US81750R1023
Symbol
MCRB
Industry

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$12.6m
Enterprise Value
$-3.0m
Net debt
positive
Cash
$15.6m
Shares outstanding
9.8m
Valuation
P/E
negative
P/S | estimate
6.7 | 1.5
EV/Sales | estimate
negative | negative
EV/FCF | ex SBC
0.1 | 0.0
P/B
0.4
Financial Health
Equity Ratio
32.0%
Return on Equity
12.9%
ROCE
-95.9%
ROIC
-93.9%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$9.2m | 488.8%
SBC as % of FCF
-
SBC Growth 1Y
-34.9%
Share Count Growth 1Y
12.3%
Shareholder Yield
-12.3%
Financials
Revenue | estimate
$1.9m | $8.3m
EBITDA
$-74.8m
EBIT
$-78.2m
Net Income
$-22.5m
Free Cash Flow | ex SBC
$-51.3m | $-60.5m
Growth
Revenue | estimate
- | 944.9%
EBITDA
29.1%
EBIT
29.0%
Net Income
-126.1%
Free Cash Flow
15.0%
Margin
Gross
-
EBITDA
-3,971.2%
EBIT
-4,154.4%
Net
-1,192.9%
Free Cash Flow | ex SBC
-2,724.1% | -3,212.0%
More
EPS
$-2.3
FCF per Share
$-5.2
Short interest
4.4%
Employees
66
Rev per Employee
$10.0k

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Seres Therapeutics Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
88%
Hold
13%

Seres Therapeutics Inc Events

Past Events
JUL
8
Special Call - Seres Therapeutics, Inc.
5 months ago
MAR
3
Special Call - Seres Therapeutics, Inc.
9 months ago
NOV
5
Q3 2025 Earnings Call
about one year ago

Financial data from Seres Therapeutics Inc

Jun '26
+/-
%
1.88 1.88
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 32 32
32% 32%
1,710%
- Research and Development Expense 47 47
14% 14%
2,481%
-75 -75
29% 29%
-3,978%
- Depreciation and Amortization 3.45 3.45
25% 25%
184%
EBIT (Operating Income) EBIT -78 -78
29% 29%
-4,161%
Net Profit -22 -22
126% 126%
-1,195%

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
18 days ago
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027 Study builds on encouraging investigator-sponsored trial (IST) results, in which 12 of 15 participants (80%) with...
Neutral
GlobeNewsWire
●
19 days ago
Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic inflammation CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics,...
Neutral
GlobeNewsWire
●
2 months ago
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to t...
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Mr. Kender
Employees 66
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today